Neil Ku­mar's Bridge­Bio lines up sub­sidiary No. 9 with a $27M shot at TTR amy­loi­do­sis

Neil Ku­mar — ex-McK­in­sey, ex-Third Rock, ex-BD guy at MyoKar­dia — set out to build a dif­fer­ent kind of biotech when he start­ed Bridge­Bio a cou­ple of years ago.

Look­ing at the mon­ey that was al­ready avail­able for plat­form plays and late-stage drug work, he was in­ter­est­ed in find­ing new mon­ey to go af­ter ear­ly-stage as­sets. So he adopt­ed an oil com­pa­ny strat­e­gy, lay­ing out the prospects for a biotech out­fit that would fo­cus on what we’ve learned from ge­net­ics dis­cov­ery over the past decade, then pluck­ing sin­gle as­sets that could be com­part­men­tal­ized in sub­sidiaries.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER